Mr. Bailey is an accomplished executive with more than 30 years of experience across all aspects of the biopharmaceutical business, with particular expertise in corporate strategy, commercial operations, business development, clinical development, corporate finance, and capital markets. He had a distinguished 16-year career with AVEO Pharmaceuticals, Inc. (AVEO), an LG Chem, Ltd. Company, where he most recently served as President and Chief Executive Officer after previously holding the roles of Chief Business Officer and Chief Commercial Officer. In 2023, Mr. Bailey led the acquisition of AVEO by LG Chem, Ltd. and has served on the Company’s Board of Directors since 2015.

Before AVEO, he was Senior Vice President of Business Development and Chief Commercial Officer at Synta Pharmaceuticals Corp. Earlier, Mr. Bailey spent nine years at ImClone Systems Inc., where he led commercial planning and the launch of ERBITUX® (cetuximab) across multiple oncology indications, drove new product planning for CYRAMZA® (ramucirumab) and PORTRAZZA® (necitumumab) and rose to Senior Vice President of Commercial Operations. Prior to ImClone, Mr. Bailey managed the cardiovascular new products development portfolio at Genentech. Mr. Bailey started his career as part of SmithKline Beecham’s executive marketing development program, where he held a variety of commercial roles, including sales, strategic planning, and product management.

Mr. Bailey received a B.S. in psychology from St. Lawrence University and an M.B.A. in international marketing from Mendoza College of Business at University of Notre Dame and continued his executive education in Finance at Harvard Business School and Board of Director Leadership at Wharton School of Business.